| Literature DB >> 23071629 |
Johannes Keller1, Silja Brink, Björn Busse, Arndt F Schilling, Thorsten Schinke, Michael Amling, Tobias Lange.
Abstract
Bioactive bone substitute materials are a valuable alternative to autologous bone transplantations in the repair of skeletal defects. However, clinical studies have reported varying success rates for many commonly used biomaterials. While osteoblasts have traditionally been regarded as key players mediating osseointegration, increasing evidence suggests that bone-resorbing osteoclasts are of crucial importance for the longevity of applied biomaterials. As no standardized data on the resorbability of biomaterials exists, we applied an in vitro-assay to compare ten commonly used bone substitutes. Human peripheral blood mononuclear cells (PBMCs) were differentiated into osteoclasts in the co-presence of dentin chips and biomaterials or dentin alone (control) for a period of 28 days. Osteoclast maturation was monitored on day 0 and 14 by light microscopy, and material-dependent changes in extracellular pH were assessed twice weekly. Mature osteoclasts were quantified using TRAP stainings on day 28 and their resorptive activity was determined on dentin (toluidin blue staining) and biomaterials (scanning electron microscopy, SEM). The analyzed biomaterials caused specific changes in the pH, which were correlated with osteoclast multinuclearity (r = 0.942; p = 0.034) and activity on biomaterials (r = 0.594; p = 0.041). Perossal led to a significant reduction of pH, nuclei per osteoclast and dentin resorption, whereas Tutogen bovine and Tutobone human strikingly increased all three parameters. Furthermore, natural biomaterials were resorbed more rapidly than synthetic biomaterials leading to differential relative resorption coefficients, which indicate whether bone substitutes lead to a balanced resorption or preferential resorption of either the biomaterial or the surrounding bone. Taken together, this study for the first time compares the effects of widely used biomaterials on osteoclast formation and resorbability in an unbiased approach that may now aid in improving the preclinical evaluation of bone substitute materials.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23071629 PMCID: PMC3468634 DOI: 10.1371/journal.pone.0046757
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Generation of osteoclasts from peripheral blood mononuclear cells (PBMC) in the presence of dentin (D) and biomaterials (BM).
Isolated PBMC were differentiated in the presence of Macrophage Colony-Stimulating Factor (M-CSF) and Receptor Activator of NF-κB Ligand (RANKL) for 28 days. 50% of the culture medium was changed every other day. Evaluation of cell morphology and quantification of mature osteoclasts was performed within the indicated region of interest (ROI). Culture wells containing exclusivley D were used as controls. Tartrate resistant acid phosphatase, TRAP; scanning electron microscopy, SEM; toluidine blue, Tolu.
Figure 2Osteoclast differentiation in the presence of various biomaterials.
A) Light microscopy images of human osteoclast cell cultures at day 0, 14 (native) and 28 (TRAP stained ) in the presence of various clinically used biomaterials. Scale bars 25 µm. B) Quantification of TRAP positive multinucleated (>3 nuclei per cell) osteoclasts per viewing field (TRAP+ MuOCL/VF) in the same cultures. C) Quantitative determination of number of nuclei per counted osteoclast (Nuclei/OCL). Control is indicated as a dotted red line. Bars represent mean ± SD relative to control of four independent experiments with PBMCs from two different donors. Asterisks indicate statistically significant differences (p<0.05 vs. control).
Figure 3Dentin resorption in the presence of non-measurable biomaterials.
A) and B) Representative scanning electron microscopy (SEM) images of selected biomaterials at day 0 and 28 (left panel) and toluidine blue stained dentin chips on day 28 (right panel) of osteoclast differentiation. Scale bars 50 µm. Note the irregular and coarse surface of biomaterials at both time points, making quantification of resorption impossible. C) Quantification of dentin resorption (mean resorption per osteoclast) cultured in the presence of biomaterials. Control is indicated as a dotted red line. Bars represent mean ± SD relative to control of four independent experiments with PBMCs from two different donors. Asterisks indicate statistically significant differences (p<0.05 vs. control).
Figure 4Resorption of biomaterial and dentin and determination of the RRC.
A) Representative scanning electron microscopy (SEM) images of assessable biomaterials at day 0 and 28 (left panel) and toluidine blue stained dentin chips on day 28 (right panel) of osteoclast differentiation. Scale bars 50 µm. Note the smooth and regular surface of biomaterials at day 0, allowing precise determination of biomaterial resorption after 28 days of osteoclast culture. B) Quantification of biomaterial (BM, upper panel) and dentin (middle panel) resorption (mean resorption per osteoclast) and calculation of the relative resorption coefficient (RRC). Control is indicated as a dotted red line. Bars represent mean ± SD of four independent experiments with PBMCs from two different donors. Superscripts indicate statistically significant differences (*p<0.05 vs. control; #p<0.05 vs. Biobon).
Figure 5Biomaterial-dependent pH-value in cell culture supernatants.
A) pH values during osteoclast differentiation in the presence of analyzed biomaterials. B) Spearman rank correlation coefficients (r) and respective p values of associations of biomaterial (BM) and dentin resorption as well as Nuclei/OCL with pH values are indicated. Asterisks indicate statistically significant differences (p<0.05).
Basic characteristics of analyzed biomaterials.
| Biomaterial | Composition | Manufacturer | Clinical studies |
| Lactosorb | L-Lactic-Acid 82%, Glycolic Acid 18% | Lorenz Surgical, Biomet Company, Indiana, USA | Edwards et al. |
| Calciresorb | β-tri-calcium phosphate >96% Hydroxylapatit <4% | Ceraver Osteal, Roissy, France | Heini and Berlemann |
| Calcibon | α-tri-calcium phosphate, calcium-hydrogen phosphate, calcium carbonate, precipitated hydroxyapatite,di-sodium hydrogen phosphate | Biomet Merck | Ooms et al. |
| Chronos | β-tri-calcium phosphate (100%) | Synthes, Oberdorf, Switzerland | Knop et al. |
| Cerasorb | β-tri-calcium phosphate (100%) | Curasan AG, Kleinostheim, Germany | Zijderveld et al. |
| Cerasorb M | β-tri-calcium phosphate (100%) | Curasan AG, Kleinostheim, Germany | Knabe et al. |
| Tutogen bovin | sterile bovine bone | Tutogen Medical, Neunkirchen, Germany | Meyer et al. |
| Tutobone human | sterile human bone | Tutogen Medical, Neunkirchen, Germany | Shin and Sohn |
| Biobon | Tri-calcium phosphate, di-calcium phosphate dihydrate | Biomet Merck, Berlin, Germany | Linhart et al. |
| Perossal | Nano crystalline hydroxylapatite 51.5%Calziumsulfate 48.5% | aap Implantate AG, Berlin, Germany | von Stechow, Rauschmann |